Baxter International, Inc. (BAX)
Stock Price Chart
Key Info
| Market Cap | 38.84B |
| Revenue (ttm) | 11.53B |
| Net Income (ttm) | 911.00M |
| Shares Out | 510.82M |
| EPS (ttm) | 1.77 |
| PE Ratio | 42.95 |
| Forward PE | 21.41 |
| Dividend | $0.98 |
| Dividend Yield | 1.29% |
Stock Quote
| Trading Day | November 24 |
| Last Price | $76.03 |
| Previous Close | $75.77 |
| Change ($) | 0.26 |
| Change (%) | 0.34% |
| Day's Open | 76.01 |
| Day's Range | 75.28 - 76.56 |
| Day's Volume | 4,589,095 |
| 52-Week Range | 69.10 - 95.19 |
More Stats
| Market Cap | 38.84B |
| Enterprise Value | 41.46B |
| Earnings Date (est) | Feb 4, 2021 |
| Ex-Dividend Date | Aug 28, 2020 |
| Shares Outstanding | 510.82M |
| Float | 509.63M |
| EPS (basic) | 1.79 |
| EPS (diluted) | 1.77 |
| FCF / Share | 2.59 |
| Dividend | $0.98 |
| Dividend Yield | 1.29% |
| Earnings Yield | 2.33% |
| FCF Yield | 3.40% |
| Payout Ratio | 52.00% |
| Shares Short | 6.05M |
| Short Ratio | 2.37 |
| Short % of Float | 1.19% |
| Beta | 0.73 |
| PE Ratio | 42.95 |
| Forward PE | 21.41 |
| P/FCF Ratio | 29.38 |
| PS Ratio | 3.37 |
| PB Ratio | 4.59 |
| Revenue | 11.53B |
| Operating Income | 1.75B |
| Net Income | 911.00M |
| Free Cash Flow | 1.32B |
| Net Cash | -2.62B |
| Net Cash / Share | -5.13 |
| Gross Margin | 42.63% |
| Operating Margin | 15.14% |
| Profit Margin | 7.90% |
| FCF Margin | 11.46% |
| ROA | 6.48% |
| ROE | 11.35% |
| ROIC | 6.90% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,362 | 11,099 | 10,584 | 10,163 | 9,968 | 10,719 | 9,413 | 13,936 | 13,893 | 12,843 |
| Revenue Growth | 2.37% | 4.87% | 4.14% | 1.96% | -7.01% | 13.87% | -32.46% | 0.31% | 8.18% | - |
| Gross Profit | 4,761 | 4,759 | 4,474 | 4,116 | 4,146 | 4,581 | 4,162 | 7,134 | 7,046 | 5,958 |
| Operating Income | 1,772 | 1,584 | 1,288 | 745 | 449 | 656 | 496 | 2,770 | 2,946 | 2,136 |
| Net Income | 1,001 | 1,546 | 602 | 4,965 | 968 | 2,497 | 2,012 | 2,326 | 2,224 | 1,420 |
| Shares Outstanding | 509 | 534 | 543 | 546 | 545 | 542 | 543 | 551 | 569 | 590 |
| Earnings Per Share | 1.93 | 2.83 | 1.08 | 9.01 | 1.76 | 4.56 | 3.66 | 4.18 | 3.88 | 2.39 |
| EPS Growth | -31.8% | 162.04% | -88.01% | 411.93% | -61.4% | 24.59% | -12.44% | 7.73% | 62.34% | - |
| Dividend Per Share | 0.85 | 0.73 | 0.61 | 0.51 | 34.28 | 2.05 | 1.92 | 1.57 | 1.27 | 1.18 |
| Dividend Growth | 16.44% | 19.67% | 20.79% | -98.53% | 1572.34% | 6.77% | 22.29% | 24.11% | 7.2% | - |
| Operating Cash Flow | 2,104 | 2,017 | 1,714 | 1,654 | 1,771 | 3,215 | 3,198 | 3,106 | 2,817 | 3,003 |
| Capital Expenditures | -696 | -659 | -616 | -719 | -911 | -925 | -706 | -1,161 | -960 | -963 |
| Free Cash Flow | 1,408 | 1,358 | 1,098 | 935 | 860 | 2,290 | 2,492 | 1,945 | 1,857 | 2,040 |
| Cash & Equivalents | 3,335 | 1,838 | 3,394 | 2,801 | 7,361 | 2,925 | 2,733 | 3,270 | 2,905 | 2,685 |
| Total Debt | 5,860 | 3,485 | 3,512 | 2,782 | 6,507 | 9,029 | 9,166 | 5,930 | 5,195 | 4,387 |
| Net Cash / Debt | -2,525 | -1,647 | -118 | 19.00 | 854 | -6,104 | -6,433 | -2,660 | -2,290 | -1,702 |
| Assets | 18,193 | 15,720 | 17,111 | 15,546 | 20,962 | 26,138 | 25,224 | 20,390 | 19,073 | 17,489 |
| Liabilities | 10,281 | 7,854 | 7,995 | 7,266 | 12,097 | 17,982 | 16,738 | 13,412 | 12,245 | 10,693 |
| Book Value | 7,882 | 7,844 | 9,124 | 8,290 | 8,846 | 8,120 | 8,463 | 6,938 | 6,585 | 6,567 |
Company Profile
Company Details
| Full Name | Baxter International, Inc. |
| Country | United States |
| Employees | 50,000 |
| CEO | José E. Almeida |
Stock Information
| Ticker Symbol | BAX |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NYSE: BAX |
Description
Baxter International, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.